Administration of immune checkpoint inhibitors at rural towns using the Teleoncology model of care—A North Queensland perspective

Abstract

AbstractObjectiveThis study aimed at evaluating the safety of administering immune checkpoint inhibitors (ICIs) and monitoring for immune‐related adverse events (irAEs) using the Teleoncology model of care.DesignA retrospective cohort study comparing two patient groups.SettingThe North Queensland Teleoncology Network (NQTN) operated by the Townsville (THHS) and Cairns Hospital Health Services (CHHS) with the Townsville Cancer Centre (TCC) acting as the control group setting.ParticipantsPatients who received ICI treatment via the NQTN between January 2015 and April 2019. Patients who received ICI at the TCC over the same time period were used for comparison.Main Outcome MeasuresRates of high‐grade irAEs and irAE‐related deaths.ResultsFifty‐two patients received a total of 822 cycles of ICIs via the Teleoncology model through NQTN. Over the same time period, 142 patients received a total of 1521 cycles at the TCC. There were no significant differences in all demographic characteristics between either group, including tumour profile and Indigenous status. There were no statistically significant differences between the rates of high‐grade irAE across multiple body organ systems (p = 0.151) and rate of hospital admissions (13.5% (NQTN) vs 5.6% (TCC), p = 0.702). There were no irAE‐related deaths in either group.ConclusionsThe results suggest that with adequate governance and clinical resources, ICIs can be administered safely using Teleoncology models to rural and remote towns.